Liminatus Pharma (LIMN) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.0 million vs $4.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | LIMN | XTLB |
|---|---|---|
| Share price | $3.69 | $1.99 |
| Market cap | $4.96M | $4.89M |
| 1-day change | -4.65% | +0.51% |
| EPS (TTM) | $-23.50 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $6.48 |
| 52-week low | $3.29 | $1.97 |
| Distance from 52-week high | -97.39% | -69.29% |
| Average volume | 453.28K | 8.62K |
| Shares outstanding | 1.34M | 2.46M |
| Employees | 1 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Healthcare · Biotechnology · 1 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Healthcare · Biotechnology · 4 employees
LIMN vs XTLB FAQ
Which is bigger, Liminatus Pharma or XTL Biopharmaceuticals?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.96M compared with $4.89M for XTL Biopharmaceuticals (XTLB).
Are Liminatus Pharma and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.